

# Modeling 2018 AHA Cholesterol guidelines in HIV: the gap in statin use and LDL target

Ciusa G<sup>1</sup>, Milic J<sup>2</sup>, Malagoli A<sup>1</sup>, Franconi I<sup>1</sup>, Raimondi A<sup>1</sup>,  
Carli F<sup>1</sup>, Zona S<sup>1</sup>, Menozzi M<sup>1</sup>,  
Tutone M<sup>1</sup>, Mussini C<sup>1</sup>, Raggi P<sup>3</sup>, Guaraldi G<sup>1</sup>

# BACKGROUND

New **AHA Cholesterol Clinical Practice Guidelines (CCPG)** were released in December 2018

## NEW GUIDELINES vs PREVIOUS GUIDELINES

- **Less strict** in recommending hypolipemic therapy in **low risk** patients
- Use **CAC score** to assess the **individual risk** in medium risk patients **to downgrade** hypolipemic prescription
- Mention **HIV** as an **(ASCVD) risk enhancer**



# OBJECTIVES



1) to assess the **gap** between **CCPG** and **real-life** statin prescription pattern in a large HIV cohort

2) to evaluate the proportion of these individuals **who reached appropriate LDL-C target.**

# METHODS

**Cross sectional** study of PLWH followed between January 2017 to December 2018 were assessed for **non-infectious comorbidities**

Patients were categorized according to CCPG mutually exclusive CV risk groups using age, **ASCVD score**, fasting LDL, DM and CAC score


Ongoing hypolipemic therapy was assessed in each group using ATC drug codes

**ASCVD score** is a tool to calculate 10-years individual risk of CV events based on age, sex, race, systolic and diastolic blood pressure, cholesterol, diabetes, cigarettes smoking, hypolipemic and anti hypertensive therapy and cardioaspirin assumption.

## POPULATION

	TOT.	M	F
SEX	1909	1411	498
MEDIAN AGE	53.55 y	53.47 y	53.68 y
VL<40 copies/ml	1890 (99.02%)	1398 (99.09%)	492 (98.8%)
CD4+	714 (533- 901)	703 (530 -892)	749 (544 -930)
CD4+ NADIR	231,93 (189,73)	237,63 (175,97)	215,51 (224,09)
ARV 3 DR.	1160 (63.56%)	886 (65.48%)	274 (58.05%)
ARV 2 DR.	562 (30.79%)	395 (29.19%)	167 (35.38%)
CVD	114 (6%)	109 (7,61%)	6 (1,2%)
DM-II	330 (17,09%)	268 (18,7%)	62 (12,45%)
OBESITY	158 (8,49%)	44 (9,26%)	114 (8,23%)
SMOKE	589 (31,82%)	447 (32,44%)	142 (30,02%)
ASCVD score	8,14	9,56	3,96

Figure 1. Secondary Prevention in Patients With Clinical ASCVD



# SECONDARY PREVENTION


114 individuals aged <75 years  
(6% of our cohort)

HIH was prescribed in **29%** of  
the cases (34 patients)


MIH was prescribed in **21.9%** of  
the cases (25 patients)

Among these patients, only  
**26.5% reached the LDL-C  
target** <70 mg/dL

Figure 2. Primary Prevention








## Diapositiva 9

---

**E1**

Elisa; 18/03/2019





## Diapositiva 10


---

E2

Elisa; 18/03/2019







## DISCUSSION



**1) Lipid lowering therapies according to the CCPG recommendations are underutilized in PLWH**

• We need tools in our clinical software to remember it!

**2) Only a minority of PLWH on appropriate hypolipemic therapy reached the LDL target raising the question of appropriate statin use in those population**

• We suggest to use more strict criteria prescribing hypolipemic therapy in HIV

**... waiting for REPRIEVE 2021**



9° WORKSHOP NAZIONALE CISAI

PREVENZIONE  
E GESTIONE  
DELLE CO-MORBIDITÀ  
ASSOCIATE  
ALL'INFEZIONE DA HIV

# GRAZIE DELL'ATTENZIONE



FONDAZIONE ASIA



BARI | 21-22 MARZO 2019

CENTRO CONGRESSI PALACE HOTEL BARI